Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest Auxilium Pharmaceuticals Inc. Stories

2013-04-29 08:26:56

-Transaction Expected to be Immediately Accretive to Adjusted Non-GAAP Net Income- CHESTERBROOK, Pa. and LAKE FOREST, Ill., April 29, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that it has completed the acquisition of Actient Holdings LLC ("Actient"), a private urology specialty therapeutics company, for $585 million in upfront cash plus certain contingent consideration and warrants to purchase Auxilium...

2013-04-29 08:26:50

- 1Q13 Net Revenues Decreased by 10% from 1Q12 to $66.2 MM - CHESTERBROOK, Pa., April 29, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the first quarter ending on March 31, 2013. The Company also highlighted important recent commercial, regulatory and clinical development progress in the first quarter of 2013. (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) For the...

2013-04-25 16:30:46

CHESTERBROOK, Pa., April 25, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the first quarter 2013 on Monday, April 29, 2013 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 8:30 a.m. ET to discuss results and highlights of the first quarter. The presentation slides to be used during the call will be available on the "For Investors" section of the...

2013-03-26 08:29:25

LYNBROOK, N.Y., March 26, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S., today announced positive, statistically significant top-line data from the Phase IIa study of XIAFLEX for the potential treatment of frozen shoulder (adhesive capsulitis). "We are very encouraged by these positive results and look forward to progress in this program which...

2013-03-25 08:26:23

- Statistically Significant Improvements in Range of Motion Compared to Exercise-Only Arm and Dose Response Supports Progression into Placebo-controlled Studies - CHESTERBROOK, Pa., March 25, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive data for collagenase clostridium histolyticum or CCH which is being developed for the potential treatment, if approved by the U.S. Food and Drug Administration...

2013-03-12 16:23:48

LYNBROOK, N.Y., March 12, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S., today announced its financial results for the fourth quarter and full year ended December 31, 2012 and provided a corporate update. "We are looking forward to the potential FDA approval of XIAFLEX for the treatment of Peyronie's disease followed by the anticipated...

2013-03-04 08:27:28

CHESTERBROOK, Pa., March 4, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Cowen and Company 33rd Annual Global Healthcare Conference to be held March 4-6, 2013 at the Marriott Copley Place in Boston. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 11:20 a.m. ET on Wednesday, March 6, 2013. (Logo:...

2013-02-26 08:28:29

- 2012 Marks First Full Year of Profitability - CHESTERBROOK, Pa., Feb. 26, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the fourth quarter and the year ended December 31, 2012. The Company also highlighted important recent commercial, regulatory and clinical development progress and provided financial guidance for 2013. (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO...

2013-02-12 08:29:33

CHESTERBROOK, Pa., Feb. 12, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Leerink Swann Global Healthcare Conference to be held February 13-14, 2013 at the Waldorf Astoria Hotel in New York City. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 2:30 p.m. ET on Thursday, February 14, 2013. (Logo:...

2013-02-12 08:29:31

CHESTERBROOK, Pa., Feb. 12, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the fourth quarter and full year 2012 on Tuesday, February 26, 2013 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the fourth quarter and full year 2012. The presentation slides to be used during the call will be available...